A drug that may curb bleeding during fibroid surgery faces its first big test

NCT ID NCT07721623

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether a single injection of carbetocin, a longer-acting relative of oxytocin, can reduce blood loss in women undergoing open abdominal surgery to remove uterine fibroids. About 900 participants will be randomly assigned to receive carbetocin or a placebo, and doctors will compare changes in hemoglobin levels and the need for blood transfusions. If it works, carbetocin could offer a simple way to make fibroid surgery safer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a synthetic hormone drug called carbetocin, similar to oxytocin but longer-acting, given as an injection to help the uterus contract and reduce bleeding
What this could lead to
If effective, carbetocin could become a standard option to reduce blood loss and transfusion needs during fibroid removal surgery.
What could go wrong
This is an early-phase trial, so the drug may not prove more effective than current options. Possible risks include allergic reactions or side effects from the medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLOOD LOSS, SURGICAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Blood Loss, Surgical Hemorrhage uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.